SCHEMBL21296967

SCHEMBL21296967

CCOC(=O)c1nn[nH]c1Sc1ccc(OC)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MAPT P10636 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TARBP2 Q15633 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PDCD4 Q53EL6 1/20 0.45
ALDH1A1 P00352 7/20 0.45
KDM4E B2RXH2 4/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HTT P42858 2/20 0.44
MAPK10 P53779 1/20 0.44
POLB P06746 2/20 0.43
GAA P10253 4/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 1/20 0.42
HSP90AA1 P07900 1/20 0.41
GABRA1 P14867 2/20 0.41
GABRG2 P18507 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296915 0.86 ALPL (0.47) NPC1RAB9AMAPTTARBP2SMN1; SMN2
SCHEMBL21296903 0.86 MAPT (0.44) MAPTTARBP2KDM4ENPSR1HTT
SCHEMBL21296943 0.83 CA1 (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL21312777 0.80 PRKAG1 (0.48) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL23001880 0.77 CYP19A1 (0.43) MAPTALDH1A1KDM4ENPSR1POLB
SCHEMBL29891693 0.77 CYP19A1 (0.43) MAPTALDH1A1KDM4ENPSR1POLB
SCHEMBL22772688 0.77 ALPL (0.46) NPC1RAB9AMAPTL3MBTL1SMN1; SMN2
SCHEMBL21296870 0.75 KDM4E (0.51) NPC1RAB9AMAPTL3MBTL1TARBP2
SCHEMBL21296980 0.74 KDM4E (0.43) NPC1RAB9AMAPTALDH1A1KDM4E
SCHEMBL21296944 0.74 MAPT (0.56) NPC1RAB9AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX NPC1 1529/4885RAB9A 2533/4885MAPT 1559/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX NPC1 1529/4885RAB9A 2533/4885MAPT 1559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.